\
&
Contact us
MSCA Research Infrastructures Health Culture and society
Adoption of the Horizon Europe work programme 2025, the amendment of the Horizon Europe ‘main’ work programme 2023-2025, and opening of calls previously planned for 6 May have been delayed. The new date for the adoption of the work programme and opening of calls is foreseen the week of 12 May. You can find the post on the EU Funding &... read more
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
MSCA Research Infrastructures Health Culture and society
The programme committee configurations gave a positive opinion on the work programme 2025. Thus, the draft texts of the Horizon Europe ‘main’ work programme 2025 and the amendment of the Horizon Europe ‘main’ work programme 2023-2025 have been pre-published. They are available on the Commission's Horizon Europe work pro... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.